Melanoma & Skin Cancer | Specialty

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

FDA Grants Nivolumab/Ipilimumab Combination Priority Review for Advanced Melanoma

September 26th 2015

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Jeffrey Weber Joins NYU Langone, Plans to Expand Clinical Trial and Immunotherapy Initiatives

September 25th 2015

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

Dr. Luke Discusses Combination Approaches on Horizon in Melanoma

September 17th 2015

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Advanced Squamous Carcinoma of the Skin: A Persistent, Growing Challenge

September 12th 2015

Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.

Dr. Grilley-Olson on Treating Patients Based on Molecular Profile

September 8th 2015

Juneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.

Dr. Piccioni on Tumor Profiles of Brain Metastases

September 2nd 2015

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Dabrafenib/Trametinib Combo Granted EU Approval for Advanced Melanoma

September 1st 2015

The combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) has been approved in the EU for advanced melanoma.

Combination Therapies Continue to Advance in Melanoma

August 31st 2015

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

Eltrombopag Approval, Cabozantinib Breakthrough Designation, Pembrolizumab Priority Review, and More

August 28th 2015

Sonidegib Approved in Europe for Basal Cell Carcinoma

August 20th 2015

The European Commission has approved the hedgehog inhibitor sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

August 18th 2015

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

Two FDA Approvals, BRAF/MEK Breakthrough Status in NSCLC, and More

August 3rd 2015

Dr. Jeffrey Trent on the Melanoma Dream Team

July 27th 2015

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

FDA Approves Sonidegib for Basal Cell Carcinoma

July 24th 2015

The FDA has approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred.

Regulatory Filings Move Dabrafenib/Trametinib Combo Closer to Full Melanoma Approval

July 24th 2015

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.

Dr. Sekulic on Molecular Testing in Advanced Melanoma

July 23rd 2015

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

European Commission Approves Pembrolizumab for Advanced Melanoma

July 22nd 2015

The European Commission has approved the PD-1 inhibitor pembrolizumab as a treatment for adult patients with unresectable or metastatic melanoma in the first-line and previously treated settings.

A Focus on Pathways: Evolving Role of Oncolytic Immunotherapy in Melanoma

July 21st 2015

Advances in the field of immunotherapy and targeted therapy have brought about new recommendations for patients with melanoma.